Factor VIII alloantibody inhibitors: Cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment

Haemophilia

Volumn 21, Issue 3, 2015, Pages 310-319

  Earnshaw, S R ^a   Graham, C N ^a   Mcdade, C L ^a   Spears, J B ^b   Kessler, C M ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b Grifols Inc   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ITI; Cost effectiveness; Costs; Decision model; Inhibitors; Prophylaxis with bypassing agents

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INFANT; LIFESPAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; COMPLICATION; DECISION MAKING; HEMORRHAGE; IMMUNOLOGY; MORTALITY; PREMEDICATION; STATISTICAL MODEL; TREATMENT OUTCOME;

BLOOD COAGULATION FACTOR INHIBITORS; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MALE; MODELS, STATISTICAL; MORTALITY; PREMEDICATION; TREATMENT OUTCOME;

EID: 84928828917     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12621     Document Type: Article

References (37)

1. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9.
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
3. World Federation of Hemophilia. Guidelines for the management of hemophilia. 2nd edition. 2012. Available at: http://www1.wfh.org/publications/files/pdf-1472.pdf. Accessed October 20, 2014.
4. Kempton CL, White GC II. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009; 113: 11-17.
5. Brown T, Lee W, Joshi A, Pashos C. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia 2009; 15: 911-17.
6. Darby S, Keeling D, Spooner R, Wan Kan S, Giangrande P, Collins P. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
7. DiMinno MND, DiMinno G, DiCapua M, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia 2010; 16: e190-201.
8. Gringeri A, Mantovani L, Scalone L, Mannucci P. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COSIS Study Group. Blood 2003; 102: 2358-63.
9. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
10. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl 1): 1-22.
11. Ogden CL, Fryar CD, Carroll MD, Flegal KM. Mean body weight, height, and body mass index, United States 1960-2002. Adv Data 2004; 347: 1-17.
12. Kulkarni R, Soucie JM, Lusher J et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from the Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009; 15: 1281-90.
13. Hay CR, DiMichele DM. International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
14. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
15. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
16. Aledort LM, Oldenburg J, Santagostino E, Yuste VJ. Rescue and primary ITI in children and adults with a single FVIII/VWF products. Paper presented at the 54th Annual Meeting and Exposition of the American Society of Hematology. December 8-11, 2012. Atlanta, GA.
17. Mariani G, Kroner B, Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
18. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
19. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003; 9:464-520. [PubMed: 12828680]
20. Oldenburg J, Jimenez-Yuste V, Peiro-Jordan R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicenter international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia 2014; 20: 83-91.
21. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
22. Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM, van Hout BA. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica 2011; 96: 738-43.
23. World Federation of Hemophilia. Guidelines for the management of hemophilia. 1st edition. 2005. Available at: http://www.guideline.gov/content.aspx?id=39323. Accessed October 20, 2014.
24. Arias E. United States life tables, 2009. Natl Vital Stat Rep 2014; 62: 1-63.
25. Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437-42.
26. HCUP Nationwide Inpatient Sample (NIS). 2010 data. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; 2013. www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed June 19, 2014.
27. US Department of Labor, US Bureau of Labor Statistics. US city average, not seasonally adjusted medical care. Available at: http://data.bls.gov/PDQ/outside.jsp?survey=cu. Accessed June 2014.
28. Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
29. HCUPnet. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; 2014. Available at: http://hcupnet.ahrq.gov/. Accessed June 10, 2014.
30. FFF Enterprises, Inc. Coagulation products. Available at: http://www.fffenterprises.com/products/coagulation-products.html. Accessed October 20, 2014.
31. American Medical Association. Current Procedural Terminology (CPT) 2014. Chicago: AMA Press, 2014.
32. Ingenix, Inc. The essential RBRVS (2014): A Comprehensive listing of RBRVS Values for CPT and HCPCS codes. Salt Lake City, UT, OptumInsight; 2014.
33. Noone D, O'Mahony B, van Dijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50.
34. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50, 000-per-QALY threshold. N Engl J Med 2014; 371: 796-7.
35. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
36. Farrugia A1, Cassar J, Kimber MC et al. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013; 19:e228-38. [PubMed: 23534877]
37. Walsh C, Miller C, Soucie M. Increased mortality risk in US hemophilia A inhibitor patients. Poster presented at XXIV Congress of the International Society on Thrombosis and Haemostasis. June 29-July 4, 2013. Amsterdam, The Netherlands.